FDA Brief

Warning letters Drugs

FDA warning letter to

Dr. Paul's Lab

High riskIssued Feb 16, 2021Posted Feb 17, 2021Center for Drug Evaluation and Research | CDER

FDA and FTC warned Dr. Paul's Lab over selling unapproved COVID-Aid Tincture with claims to prevent or treat COVID-19.

What happened

FDA reviewed drpaulslab.net on January 28, 2021, and FTC reviewed it on February 9, 2021. The website directed consumers to dealers, including drsarahsessentials.com, which offered "COVID-Aid Tincture" for sale in the U.S. FDA found the product was intended to mitigate, prevent, treat, diagnose, or cure COVID-19, citing label directions telling users to take 1 cc under the tongue 4–6 times daily if illness was suspected.

What FDA found

  1. The product is an unapproved new drug because it is intended to treat or prevent COVID-19 without FDA approval.

    section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)
  2. The product is misbranded because its labeling makes misleading COVID-19 claims.

    section 502 of the FD&C Act, 21 U.S.C. § 352
  3. The company is prohibited from introducing the product into interstate commerce.

    sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)
  4. The company advertised that the product can prevent, treat, or cure disease without competent and reliable scientific evidence.

    FTC Act, 15 U.S.C. 41 et seq.
  5. Deceptive COVID-19 treatment claims can carry civil penalties of up to $43,792 per violation.

    COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260

What FDA wants

FDA asks the company to immediately stop selling unapproved products claimed to prevent or treat COVID-19 and, within 48 hours, email COVID-19-Task-Force-CDER@fda.hhs.gov with the steps taken and documentation to prevent recurrence.

Who should pay attention

  • makers and sellers of COVID-19-related tinctures or supplements
  • retailers and websites that list or link to such products
  • quality teams reviewing disease claims on product labels and websites

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk